A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants

NCTID	NCT05757245 (View at clinicaltrials.gov)
Description	This is a non-randomized, open label, single-site, single-dose, phase 1 study in up to 5 participants (between 5 and 35 years of age, inclusive) with Transfusion-dependent α-thalassemia. The study will evaluate the safety and efficacy of autologous hematopoietic stem cell transplantation (HSCT) using GMCN-508A Drug Product \[autologous CD34+ hematopoietic stem cells transduced with GMCN-508A lentiviral vector encoding the human α-globin gene\]. (Show More)
Development Status	Active
Indication	Transfusion-dependent Alpha-Thalassemia
Disease Ontology Term	DOID:1099
Compound Name	GMCN-508A
Sponsor	First Affiliated Hospital of Guangxi Medical University
Funder Type	Other
Recruitment Status	Recruiting (Click here for study contact information)
Enrollment Count	5
Results Posted	Not Available

Target Gene/Variant	HBA
Therapy Type	Gene transfer
Therapy Route	Ex-vivo
Mechanism of Action	Functional gene replacement
Route of Administration	Intravenous
Drug Product Type	Autologous cells
Target Tissue/Cell	CD34+ cells
Delivery System	Viral transduction
Vector Type	LV
Editor Type	none
Dose 1	Transduced CD34+ cells
Dose 2
Dose 3
Dose 4
Dose 5

No.of Trial Sites	1
Locations	China

No External Links Available.